|Articles|July 30, 2021

A Clinical Decision Support Strategy Boosted Influenza Vaccination Rates Among Hospitalized Children

Author(s)Jonna Lorenz

A clinical decision support (CDS) strategy including a default influenza vaccine order for eligible patients, a nursing script using a presumptive strategy, and education for clinicians, was associated with significant improvement in vaccination rates among hospitalized children, a new study showed.

Incorporating a clinical decision support (CDS) strategy was associated with significantly higher odds of hospitalized children receiving the influenza vaccine, a recent study found.

The quality improvement study, published in JAMA Network Open, examined 17740 hospitalizations at 3 hospitals in a tertiary pediatric health system. The patients, who were hospitalized during 3 influenza seasons between 2018 and 2020, were divided among intervention groups and concurrent controls and historical controls.

“Clinical decision support (CDS) in the electronic health record (EHR) that integrates with clinicians' workflow can significantly improve use of evidence-based practices such as providing influenza vaccine to eligible hospitalized children,” Evan Orenstein, MD, pediatric hospitalist and chief medical information officer, Children's Healthcare of Atlanta, Emory University, told Contagion. “Many QI are limited to pre/post designs (i.e. what was the vaccination rate before and after the intervention). These approaches are susceptible to inappropriate conclusions from secular trends -- for example we know the vaccination rate naturally falls the later we get in the flu season. Step-wise implementations that provide both historical and concurrent controls are practical and improve the scientific rigor of QI interventions.”

The study examined a CDS intervention that included placing a default influenza vaccine order into admission order sets for eligible patients, a nursing script to offer the vaccine using a presumptive strategy, and education for clinicians including links to references.

“Small changes in CDS design can have a large impact on behavior,” Orenstein said. “For example, adding links to references justifying influenza vaccine for immunocompromised children or for those on steroids changed how physicians behaved during usability testing. Similarly, providing nursing flexibility by placing the influenza vaccine order in admission order sets instead of at the time of discharge made it easier to get the vaccine in despite a busy hospitalization. Finally, we were surprised that the vaccination rate among our concurrent controls (hospitalizations during the same season where we intervened but who were not exposed to our CDS intervention) was significantly higher than our historical controls (hospitalization in the prior flu season). We suspect this may have been due to the fact that physicians were seeing influenza vaccine orders in their workflow more often for the intervention group and were therefore reminded about the vaccine more often.”

Among the study participants, the average age was 8 years, 52% were boys, 50% were Black, 43% were White, and 64% had public insurance. The study authors noted that hospitalized children are at higher risk for morbidity and mortality related to influenza, but vaccine coverage is lower than the national average for this group.

The odds of receiving the influenza vaccine were 3.25 (95% CI, 2.94-3.59) times higher in the intervention group and 1.28 (95% CI, 1.15-1.42) times higher in concurrent controls than in historical controls, the study found. An influenza vaccine was ordered for 4199 out of 5449 (77%) hospitalizations in the intervention group and administered during 1676 (31%) hospitalizations. In the concurrent control group, an influenza vaccine was ordered during 1488 (27%) of hospitalizations and administered during 1051 (19%). In the historical control group, an influenza vaccine was ordered during 1024 (15%) hospitalizations and administered during 912 (14%).

The odds of receiving the vaccine were highest early in the influenza season, declining by 3.7% with each additional week into the season. Age also was evaluated, with adolescents ages 13 to 17 being 28% less likely to receive the vaccines than children ages 6 to 23 months.

Further research is underway to improve influenza vaccination rates among children.

“While we saw significant improvements in flu vaccination rates, even among our intervention group only 31% of eligible hospitalizations had a flu vaccine administered,” Orenstein said. “We are undergoing a thorough analysis of the reasons why flu vaccines get ordered but not administered and developed additional CDS interventions for the 2020-2021 influenza season. We will be evaluating the effectiveness of those in concert with the interventions described here.”

“We are hoping to expand the use of this CDS beyond a single institution to determine if this pattern is effective in other health systems,” he added. “We are evaluating similar strategies in different care settings—i.e. the emergency department and ambulatory specialty clinics.”

The importance of vaccination is heightened amid the COVID-19 pandemic. Investigators are studying the possible benefits of co-administration of COVID-19 and influenza vaccines.

Efforts to improve vaccination rates and influenza vaccines are ongoing.

The National Institutes of Health recently began a Phase 1 human trial of a universal influenza vaccine, FluMos-v1, which is designed to stimulate antibodies against multiple influenza virus strains.


Related to this article

NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.